), a global leader in medical devices used in critical care and
surgery, recently launched its new Arrow SureBlock Spinal
Anesthesia collection. This will enhance Teleflex's portfolio of
spinal anesthesia products released in 2009.
The new Arrow SureBlock kit is designed to meet the changing
needs of the anesthesia provider. Teleflex's latest offering under
the Arrow SureBlock brand will expand its line of Anesthesia and
Airway Management products in its largest segment -- Critical Care.
Revenues from the Critical Care segment edged up 0.2% year over
year to $254.1 million in the second quarter.
Earlier, Teleflex announced the twin acquisitions of Willemstad,
Netherlands-based LMA International N.V. and LMA's laryngeal mask
supraglottic airway business from Intavent Direct Limited. The
acquisitions along with the new Arrow SureBlock are expected to
boost revenues of the Anesthesia and Airway Management product
Per management, the revamped Arrow SureBlock collection of kits
will promote patient safety and reliability for anesthesiologists.
The launch underlines Teleflex's commitment to innovation and
product line extension.
The Arrow SureBlock collection includes complete medication kits
for spinal anesthesia which is integrated with the Sprotte spinal
needle. It has been clinically testified that use of Sprotte spinal
needle curtails the occurrence of postdural puncture headaches. The
new line of kits will include a glass barrel syringe to positively
identify and access the spinal space in a reduced time span.
Teleflex, headquartered in Limerick, Pennsylvania, is a
manufacturer and provider of medical devices used in critical care
and surgery. Its move to divest OEM Orthopedic division along with
the strategy of developing new, innovative products should help
improve its financial performance in the long run. The company's
focus on profitable and consistent growth with new product
introduction and portfolio expansion via acquisition is expected to
), which operate in similar business segments, present a tough
competitive landscape for Teleflex. Additionally, the company
operates in a stringent regulatory environment. The demand for its
products is susceptible to healthcare reimbursement systems in the
domestic as well as the international market.
Teleflex currently retains a Zacks #4 Rank, which translates
into a short-term Sell rating.
BARD C R INC (BCR): Free Stock Analysis Report
CAREFUSION CORP (CFN): Free Stock Analysis
COVIDIEN PLC (COV): Free Stock Analysis Report
TELEFLEX INC (TFX): Free Stock Analysis Report
To read this article on Zacks.com click here.